Beihai Gofar Chuanshan Biological Co (600538) Fair Value & Analysis
Basic Materials · CN · Market cap 2.8B CNY
Fair value as of: Aug 9, 2026
From 1 valuation models · updated yesterday
Share price +2.3% over the past month.
Below-average quality, and screening another 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥0.5600). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range ¥2.95 – ¥10.70 · fair‑value band ¥0.3700 – ¥0.5600 · the ¥5.39 price screens above the ¥0.5600 fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
Beihai Gofar Chuanshan Biological Co (600538) currently trades at ¥5.39, while our model-based Fair Value estimate is ¥0.5600, implying the stock looks roughly 89.6% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Beihai Gofar Chuanshan Biological Co generated revenue of 332M CNY at a net margin of -29.6%. Revenue grew 5.1% year over year. It earns a return on equity of -13.1%. The balance sheet holds a net cash position of 108M CNY. Fundamentals as of Aug 9, 2026
Our scenario range runs from ¥0.3700 (bear case) to ¥0.5600 (bull case); at ¥5.39, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -13% fair-value upside, at -90%, 600538 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 600538 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments.
Full company description
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distributors, and allocations. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; brand gastrointestinal granules, honeysuckle oral solution, and children's syrup under the Guofa brand; and traumatic injury medicated wine, and sea snake medicated wine under the Haima brand. In addition, the company produces and sells forensic DNA testing equipment, reagents, and consumables; and provides technical services, including DNA testing services. Further, it engages in culture and arts activities; and provision of technical services. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beihai Gofar Chuanshan Biological Co reported revenue of ¥328M in FY2025 versus ¥425M in FY2021, a compound −6.2%/yr. Reported net income was −¥87.6M in FY2025.
600538 screens 90% overvalued. Compare with Corteva, Inc →
Peer Group
Agricultural Inputs · 179 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $86.07 | $27.81 | -68% |
| Nutrien Ltd NTR | C$94.23 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥24.93 | ¥21.26 | -15% |
| CF Industries Holdings CF | $119.19 | $161.00 | +35% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 451.30 | kr 67.25 | -85% |
| Yunnan Yuntianhua Co 600096 | ¥30.17 | ¥42.12 | +40% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥42.59 | ¥38.01 | -11% |
| Coromandel International Limited COROMANDEL | ₹2,034 | ₹1,129 | -44% |
| UPL Limited UPL | ₹594.75 | ₹387.06 | -35% |
Compare Beihai Gofar Chuanshan Biological Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Beihai Gofar Chuanshan Biological Co (600538) overvalued or undervalued?
What is the fair value of 600538?
What is the quality score of 600538?
What is the revenue of Beihai Gofar Chuanshan Biological Co (600538)?
What is the net profit margin of 600538?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beihai Gofar Chuanshan Biological Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.